Capricor Therapeutics (NASDAQ: CAPR) Soars Over 500% After HOPE‑3 Phase 3 Win: What It Means for the Stock Now
Capricor Therapeutics’ stock exploded higher on December 3, 2025 after the biotech announced that its pivotal Phase 3 HOPE‑3 trial of Deramiocel in Duchenne muscular dystrophy met both its primary and key secondary endpoints.GlobeNewswire Below is a deep dive into today’s news, the regulatory backdrop, the company’s finances and pipeline, and how analysts have been thinking about CAPR stock heading into this inflection point.